A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: SHR-A1811|DRUG: Pyrotinib
Sponsor: Shengjing Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.